百济神州（688235）：首次覆盖：泽布替尼持续放量，实体瘤加速推进

首次覆盖: 泽布替尼持续放量，实体瘤加速推进 百济神州-U(688235) | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 17,423 | 27,214 | 37,261 | 45,308 | 51,151 | | (+/-)% | 82.1% | 56.2% | 36.9% | 21.6% | 12.9% | | 净利润(归母) | -6,716 | -4,978 | 2,046 | 4,260 | 5,304 | | (+/-)% | 50.8% | 25.9% | 141.1% | 108.2% | 24.5% | | 每股净收益(元) | -4.67 | -3.46 | 1.42 | 2.96 | 3.69 | | 净资产收益率(%) | -26.8% | -20.6% | 7.8% | 13.9% | 14.8% | | 市盈率(现价&最新股本摊薄) | — | — | 196.18 | 94.21 | 75.6 ...